RayKnowChina Research Map
Shortlist0

RecruitingMyasthenia gravisPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

An open trial on myasthenia gravis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 11 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 11

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Shandong First Medical University山东第一医科大学第一附属医院(山东省千佛山医院)JinanHospital page
  2. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  3. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  4. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  5. Study siteJiangxi Provincial People's Hospital江西省人民医院NanchangHospital page
  6. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  7. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  8. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  9. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  10. Study siteTangdu Hospital空军军医大学唐都医院Xi'anHospital page
  11. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06447597, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Pregnant and lactating women;

    Exclusion criterion 8

    Fertile female subjects do not agree to use effective contraception from signing the informed consent form to 1 years after the last dose.

    Exclusion criterion 9

    Sexually active male subjects who do not intend to use an effective contraceptive method during the trial period or within1 years after the last dose, or male subjects who plan to donate sperm during the trial or within 1 year after the last dose;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06447597, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign informed consent form;
  • Subjects with generalized myasthenia gravis;
  • Serum AchR(Acetylcholine receptor)-Ab or MUSK-Ab was positive during screening;
  • MG-ADL ≥5 at screening and baseline;
  • Before randomization, subjects received at least one gMG stable dose of SoC, and maintain a stable dose throughout the test;
  • Subjects agree to use effective contraceptive methods for contraception from signing the informed consent form to 1 year after the last dose. Female subjects considered fertile by the investigator must have negative serum pregnancy tests before the first dose.

Exclusion Criteria:

  • Subjects with MGFA I and V type;
  • Subjects usingprescribed drugs;
  • Subjects with a prescribed disease or history of disease;
  • The subjects has prescribed examination abnormalities that are assessed as unsuitable for participation in the study by the investigator;
  • Known history of severe allergic reaction to humanized monoclonal antibodies, or known allergy to any component of B007;
  • Subjects who received live vaccine at the specified time before the first dose and are expected to receive the vaccine at the specified time after the last dose;
  • Subjects who have received major surgery or participated in other clinical trials within the prescribed time before screening;
  • Pregnant and lactating women;
  • Fertile female subjects do not agree to use effective contraception from signing the informed consent form to 1 years after the last dose.
  • Sexually active male subjects who do not intend to use an effective contraceptive method during the trial period or within1 years after the last dose, or male subjects who plan to donate sperm during the trial or within 1 year after the last dose;
  • A history of alcohol or drug abuse within the past 12 months;
  • Other conditions deemed unsuitable for participation in this study by the researchers.

Quoted from ClinicalTrials.gov, NCT06447597, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06447597, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06447597